Proteomic analyses reveal misregulation of LIN28 expression and delayed timing of glial differentiation in human iPS cells with MECP2 loss-of-function

Jean J. Kim*, Jeffrey N. Savas, Meghan T. Miller, Xindao Hu, Cassiano Carromeu, Mathieu Lavallée-Adam, Beatriz C.G. Freitas, Alysson R. Muotri, John R. Yates, Anirvan Ghosh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Rett syndrome (RTT) is a pervasive developmental disorder caused by mutations in MECP2. Complete loss of MECP2 function in males causes congenital encephalopathy, neurodevelopmental arrest, and early lethality. Induced pluripotent stem cell (iPSC) lines from male patients harboring mutations in MECP2, along with control lines from their unaffected fathers, give us an opportunity to identify some of the earliest cellular and molecular changes associated with MECP2 loss-of-function (LOF). We differentiated iPSC-derived neural progenitor cells (NPCs) using retinoic acid (RA) and found that astrocyte differentiation is perturbed in iPSC lines derived from two different patients. Using highly stringent quantitative proteomic analyses, we found that LIN28, a gene important for cell fate regulation and developmental timing, is upregulated in mutant NPCs compared to WT controls. Overexpression of LIN28 protein in control NPCs suppressed astrocyte differentiation and reduced neuronal synapse density, whereas downregulation of LIN28 expression in mutant NPCs partially rescued this synaptic deficiency. These results indicate that the pathophysiology of RTT may be caused in part by misregulation of developmental timing in neural progenitors, and the subsequent consequences of this disruption on neuronal and glial differentiation.

Original languageEnglish (US)
Article numbere0212553
JournalPloS one
Volume14
Issue number2
DOIs
StatePublished - Feb 2019

Funding

This work was supported by grants from the California Institute for Regenerative Medicine (CIRM) TR2-01814 and TR4-06747 (to A.R.M), and RB3-05229 (to A.G. and J.J.K.). The Muotri lab is supported by National Institutes of Health (NIH) through the NIH Director’s New Innovator Award Program (1-DP2-OD006495-01), an R01 MH100175-01 from NIMH and from the International Rett Syndrome Foundation (IRSF grant # 2915). J.N.S. was supported by an F. Hoffman-La Roche Postdoctoral Fellowship Award (SFP2063), 1K99DC013805-01 from National Institute on Deafness and Other Communication Disorders, and The Hartwell Foundation, Individual Biomedical Research Award. M.L.-A. was supported by a postdoctoral fellowship from the Fonds de Recherche du Québec–Nature et Technologies (FRQNT). The Yates’ lab is supported by UOW/R41GM103533, MH–2 R01 MH067880-11 and 1 R01 MH100175-01, and National Institute of General Medical Sciences P41 GM103533. The funder (F. Hoffmann-La Roche) provided support in the form of salaries for authors (MTM and AG), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Proteomic analyses reveal misregulation of LIN28 expression and delayed timing of glial differentiation in human iPS cells with MECP2 loss-of-function'. Together they form a unique fingerprint.

Cite this